Organogenesis Holdings (ORGO) Cash from Investing Activities (2018 - 2026)

Organogenesis Holdings' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$3.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 13.24% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$13.7 million (down 19.54% YoY), while the FY2025 annual figure was -$14.2 million, down 41.06% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$3.1 million, up from -$4.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$1.9 million in Q2 2024, with the low at -$10.7 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is -$3.6 million (2025), against an average of -$5.0 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities plunged 103.86% in 2022, then surged 74.93% in 2024.
• Organogenesis Holdings' Cash from Investing Activities stood at -$10.7 million in 2022, then jumped by 68.81% to -$3.3 million in 2023, then slipped by 1.11% to -$3.4 million in 2024, then sank by 38.41% to -$4.7 million in 2025, then jumped by 32.37% to -$3.1 million in 2026.
• Business Quant data shows ORGO's Cash from Investing Activities at -$3.1 million in Q1 2026, -$4.7 million in Q4 2025, and -$2.2 million in Q3 2025.